Earnings Releases·Nov 4, 2026, 7:10 AM ET

uniQure — Third Quarter 2026 Earnings Summary

Revenue increased to $5.2 million from $3.7 million year-over-year, driven by higher license revenue, while the net loss narrowed to $61.2 million ($0.88 per share) from $80.5 million ($1.38 per share) in the prior year period.
The FDA granted Priority Review for the BLA of ifezuntirgene inilparvovec (AMT-130) for Huntington's disease, setting a PDUFA target action date of May 1, 2027, with U.S. patient screening for the required confirmatory study expected to begin by the end of 2026.
Cash, cash equivalents, and investment securities rose to $768.4 million as of September 30, 2026, providing sufficient funding to cover operating expenses through 2030.
The U.K. MHRA validated the Marketing Authorization Application for AMT-130, and the company resumed enrollment for the AMT-191 Fabry disease study in August 2026 following the resolution of prior safety pauses.